

# Stphane Depil

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/483886/stephane-depil-publications-by-year.pdf>  
**Version:** 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60 papers	2,405 citations	26 h-index	48 g-index
102 ext. papers	3,162 ext. citations	6.8 avg, IF	5.22 L-index

#	Paper	IF	Citations
60	Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy.. <i>Science Advances</i> , <b>2022</b> , 8, eabj3671	14.3	4
59	Off-the-Shelf Allogeneic CAR-T Cells or Other Immune Effector Cells <b>2022</b> , 51-54		
58	691 Identification of shared tumor epitopes from endogenous retroviruses inducing high avidity cytotoxic T cells for cancer immunotherapy <b>2021</b> , 9, A719-A719		
57	Toward Off-the-shelf Allogeneic CAR T cells. <i>Advances in Cell and Gene Therapy</i> , <b>2020</b> , 3, e86	1.2	12
56	Human Endogenous Retroviruses (HERVs): Shaping the Innate Immune Response in Cancers. <i>Cancers</i> , <b>2020</b> , 12,	6.6	19
55	'Off-the-shelf' allogeneic CAR T cells: development and challenges. <i>Nature Reviews Drug Discovery</i> , <b>2020</b> , 19, 185-199	64.1	267
54	Cold Tumors: A Therapeutic Challenge for Immunotherapy. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 168	8.4	338
53	Cancer-Associated Fibroblasts Produce Netrin-1 to Control Cancer Cell Plasticity. <i>Cancer Research</i> , <b>2019</b> , 79, 3651-3661	10.1	30
52	Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. <i>Journal of Biological Chemistry</i> , <b>2019</b> , 294, 5430-5437	5.4	62
51	Modulation of chimeric antigen receptor surface expression by a small molecule switch. <i>BMC Biotechnology</i> , <b>2019</b> , 19, 44	3.5	39
50	A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors. <i>Annals of Oncology</i> , <b>2019</b> , 30, v159	10.3	6
49	Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	34
48	Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality. <i>Nature Communications</i> , <b>2019</b> , 10, 5100	17.4	23
47	Neoepitopes-based vaccines: challenges and perspectives. <i>European Journal of Cancer</i> , <b>2019</b> , 108, 55-60	7.5	11
46	Pattern recognition receptors: immune targets to enhance cancer immunotherapy. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1756-1766	10.3	78
45	Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat. <i>Oncotarget</i> , <b>2017</b> , 8, 56210-56227	3.3	12
44	Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma. <i>Gene</i> , <b>2016</b> , 580, 134-143	3.8	5

43	Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers. <i>Cancer Cell</i> , <b>2016</b> , 29, 173-85	24.3	52
42	Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 177-87	8.7	49
41	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 423-31	4.3	25
40	TIPIN depletion leads to apoptosis in breast cancer cells. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1580-98	7.9	14
39	HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 149, 81-9	4.4	16
38	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 14139-52	3.3	19
37	Abstract 2921: Preclinical characteristics of NP137, a first-in-class monoclonal antibody directed against netrin-1 and inducing dependence receptors-mediated cell death <b>2015</b> ,		2
36	Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer. <i>Cell Death and Disease</i> , <b>2014</b> , 5, e1423	9.8	31
35	Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 875-90	4.5	42
34	Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. <i>PLoS ONE</i> , <b>2014</b> , 9, e80836	3.7	34
33	Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts. <i>PLoS ONE</i> , <b>2014</b> , 9, e91325	3.7	30
32	Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor. <i>Pharmaceutical Research</i> , <b>2013</b> , 30, 2640-53	4.5	8
31	Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 2791-7	7.5	29
30	Decoding and unlocking the BCL-2 dependency of cancer cells. <i>Nature Reviews Cancer</i> , <b>2013</b> , 13, 455-65	31.3	170
29	The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6520-31	12.9	112
28	Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. <i>Cancer Research</i> , <b>2013</b> , 73, 813-23	10.1	125
27	S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 1749-62	6.1	69
26	Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. <i>Cell Death and Disease</i> , <b>2013</b> , 4, e738	9.8	27

25	TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e63742	1.7	93
24	524 LRP5: a Potential Therapeutic Target in Triple-negative Breast Cancer. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 161-162	7.5	
23	Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. <i>Trends in Biotechnology</i> , <b>2012</b> , 30, 575-82	15.1	82
22	EBV Latency II-derived peptides induce a specific CD4+ cytotoxic T-cell activity and not a CD4+ regulatory T-cell response. <i>Journal of Immunotherapy</i> , <b>2012</b> , 35, 254-66	5	12
21	Abstract 5130: Integrative approaches for the identification of therapeutic targets in basal like breast cancer from multi-level molecular data <b>2012</b> ,		2
20	Antitumor evaluation of the new Bcl-2/Bcl-xl inhibitor S44563 in primary human uveal melanoma xenografts. <i>Acta Ophthalmologica</i> , <b>2012</b> , 90, 0-0	3.7	
19	Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylase (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients. <i>Blood</i> , <b>2012</b> , 120, 3643-3643	2.2	2
18	Comparative analysis of naïve and memory CD4+ and CD8+ T-cell subsets in bone marrow and G-CSF-mobilized peripheral blood stem cell allografts: impact of donor characteristics. <i>Experimental Hematology</i> , <b>2007</b> , 35, 861-71	3.1	14
17	Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. <i>Annals of Oncology</i> , <b>2007</b> , 18, 370-5	10.3	37
16	Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies. <i>Journal of Immunotherapy</i> , <b>2007</b> , 30, 215-26	5	23
15	Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection. <i>Vaccine</i> , <b>2007</b> , 25, 5927-37	4.1	15
14	Peptide-binding assays and HLA II transgenic Abeta degrees mice are consistent and complementary tools for identifying HLA II-restricted peptides. <i>Vaccine</i> , <b>2006</b> , 24, 2225-9	4.1	9
13	A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy. <i>Leukemia</i> , <b>2006</b> , 20, 1557-65	10.7	43
12	Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival. <i>Leukemia Research</i> , <b>2005</b> , 29, 665-71	2.7	10
11	Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. <i>British Journal of Haematology</i> , <b>2005</b> , 129, 706-7	4.5	5
10	Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have an human leukocyte antigen-identical related donor: a long-term study of 97 consecutive patients. <i>Leukemia and Lymphoma</i> , <b>2005</b> , 46, 841-9	1.9	4
9	Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 2481-4	1.9	9
8	Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , <b>2004</b> , 33, 531-4	4.4	45

7	A case of refractory anemia with 17p- syndrome following azathioprine treatment for heart transplantation. <i>Leukemia</i> , <b>2004</b> , 18, 878	10.7	6
6	Efficient generation of antileukemic autologous T cells by short-term culture and gamma-irradiation of myeloid leukemic cells. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 793-8	7.4	8
5	Impact of Small Bowel Exploration Using Video-Capsule Endoscopy in the Management of Acute Gastrointestinal Graft-versus-Host Disease. <i>Transplantation</i> , <b>2004</b> , 78, 1697-701	1.8	49
4	Chemotherapy increases transgene expression in leukemic cells. <i>Journal of Gene Medicine</i> , <b>2003</b> , 5, 852-859	3.9	5
3	SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. <i>Leukemia</i> , <b>2003</b> , 17, 1678-9	10.7	19
2	Primary central nervous system lymphoma in immunocompetent adults: poor results mainly associated with high treatment related toxicities. <i>Leukemia and Lymphoma</i> , <b>2002</b> , 43, 1819-22	1.9	6
1	Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukemia patients. <i>Leukemia</i> , <b>2002</b> , 16, 254-9	10.7	106